Axel Svedbom

Axel Svedbom

Auto-generated profile, based on publicly available information

Axel Svedbom

Division of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2014 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
JKJohn A Kanis
John A Kanis
ASAxel Svedbom
Axel Svedbom
NHNicholas Harvey
Nicholas Harvey
EMEugene V McCloskey
Eugene V McCloskey
Click on the article title to read more.

18 January 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
LPL. Pasquali
L. Pasquali
ASA. Svedbom
A. Svedbom
ASA. Srivastava
A. Srivastava
ERE. Rosén
E. Rosén
ULU. Lindqvist
U. Lindqvist
ESEnikö Sonkoly
Enikö Sonkoly

1 January 2014 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
ASA Svedbom
A Svedbom
JDJ Dalén
J Dalén
CMC Mamolo
C Mamolo
JCJ Cappelleri
J Cappelleri
LML Mallbris
L Mallbris
MSM Ståhle
M Ståhle
Several studies have shown excess risk for a number of comorbidities in patients with psoriasis comp...

3 July 2019 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
ASA. Svedbom
A. Svedbom
PHP. Hadji
P. Hadji
EHE. Hernlund
E. Hernlund
RTR. Thoren
R. Thoren
EME. McCloskey
E. McCloskey
BSBjörn Stollenwerk
Björn Stollenwerk

12 May 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
ASA. Svedbom
A. Svedbom
MSM. Ståhle
M. Ståhle
Background: Patients treated with systemics for moderate‐to‐severe psoriasis have increased risk of cardiovascular disease (CVD). However, to the best of our knowledge, there are no data on the association between clinical disease activity and future cardiovascular events in this population. Such data could help identify patients at increased CVD risk and inform the potential for CVD prevention with effective psoriasis treatment.Objective: To estimate the association between the Psoriasis Area and Severity Index (PASI) and cardiovascular events defined as hospitalization for CVD and cardiovascular death.Methods: We linked prospectively collected data on PASI and CVD risk factors to population‐based administrative data on hospitalizations and causes of death. We estimated the association between PASI and cardiovascular events using Cox proportional hazard models with PASI and Framingham 10‐year cardiovascular risk as time‐varying covariates.Results: A total of 767 patients with 6264 PASI scores were included. After adjusting for 10‐year cardiovascular risk and prior CVD, a one‐point increase in PASI was associated with a hazard ratio of 1.04 (95% CI: 1.01–1.07) for cardiovascular events. The findings were robust in sensitivity analyses.Conclusion: PASI is an independent marker for future cardiovascular events in patients with moderate‐to‐severe psoriasis.

1 July 2016 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
ASA Svedbom
A Svedbom
JDJ Dahlén
J Dahlén
CMC Mamolo
C Mamolo
JCJ Cappelleri
J Cappelleri
LML Mallbris
L Mallbris
MSM Ståhle
M Ståhle
Estimates of direct and indirect costs of psoriasis are limited. The aim of this study was to estimate: (i) costs in patients with psoriasis...